Literature DB >> 10526291

Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice.

C Theodossiou1, N Skrepnik, E G Robert, C Prasad, T W Axelrad, D V Schapira, J D Hunt.   

Abstract

BACKGROUND: Thyroid hormones are endocrine modulators of several vital processes that are crucial to tumor growth and differentiation. Several anecdotal reports in the literature suggest that some histologic types of carcinoma may remain in a dormant state for prolonged periods of time in patients with hypothyroidism, with eventual progression of the disease once the decreased thyroid function is identified and corrected.
METHODS: Oral propylthiouracil (PTU) was used to induce hypothyroidism in athymic nude mice that were subsequently inoculated with lung adenocarcinoma and prostate adenocarcinoma cells. Mice were also treated with a combination of PTU and thyroxine, which resulted in hyperthyroid levels of T(4).
RESULTS: Subcutaneous lung and prostate xenografts grew significantly more slowly in hypothyroid mice treated with PTU than in euthyroid or hyperthyroid mice, regardless of treatment with PTU. Tumors grew well in groups of mice that were changed from a hypothyroid state to a euthyroid state by withdrawal of oral PTU. Administration of PTU 3 weeks after tumor inoculation also caused the tumor growth to slow significantly compared with tumors in mice that did not receive PTU. Mice that received PTU and thyroxine had tumors that grew as well as the tumors in euthyroid control animals.
CONCLUSIONS: Our study indicates that human lung and prostate tumors do not grow well in hypothyroid nude mice, and that rendering these animals euthyroid has a significant impact on the growth rate of these tumors. Furthermore, in vitro and in vivo data indicated that this was not a result of an interaction of the tumor cells with PTU, but rather a result of the hypothyroid state. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526291

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Authors:  Rebecca L Brown
Journal:  Target Oncol       Date:  2011-11-19       Impact factor: 4.493

Review 2.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

Review 3.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

4.  The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.

Authors:  E Shinderman-Maman; K Cohen; C Weingarten; D Nabriski; O Twito; L Baraf; A Hercbergs; P J Davis; H Werner; M Ellis; O Ashur-Fabian
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

5.  Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

Authors:  Aleck Hercbergs; Rebecca E Johnson; Osnat Ashur-Fabian; David H Garfield; Paul J Davis
Journal:  Oncologist       Date:  2014-11-19

6.  Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines.

Authors:  Ruey-Nan Chen; Ya-Hui Huang; Ya-Chu Lin; Chau-Ting Yeh; Ying Liang; Shen-Liang Chen; Kwang-Huei Lin
Journal:  Endocrinology       Date:  2008-05-08       Impact factor: 4.736

7.  Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis.

Authors:  H C Puhr; P Wolf; A S Berghoff; S F Schoppmann; M Preusser; Aysegul Ilhan-Mutlu
Journal:  Horm Cancer       Date:  2019-12-28       Impact factor: 3.869

8.  Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4.

Authors:  Sarah A Hackenmueller; Maja Marchini; Alessandro Saba; Riccardo Zucchi; Thomas S Scanlan
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

9.  Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.

Authors:  Bénédicte F Jordan; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2012-05-21       Impact factor: 5.810

10.  Low thyroid hormone levels improve survival in murine model for ocular melanoma.

Authors:  Ido Didi Fabian; Mordechai Rosner; Ina Fabian; Vicktoria Vishnevskia-Dai; Ofira Zloto; Elena Shinderman Maman; Keren Cohen; Martin Ellis; Hung-Yun Lin; Aleck Hercbergs; Paul J Davis; Osnat Ashur-Fabian
Journal:  Oncotarget       Date:  2015-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.